Department of Medicine, The University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Vaccine. 2011 Oct 26;29(46):8175-8. doi: 10.1016/j.vaccine.2011.09.005. Epub 2011 Sep 13.
Our previous studies have shown that recombinant multivalent vaccines containing amino-terminal M protein fragments from as many as 26 different serotypes of group A streptococci (GAS) evoked opsonic antibodies in animals and humans. In the present study, we constructed a new 30-valent vaccine containing M protein peptides from GAS serotypes prevalent in North America and Europe. The vaccine was immunogenic in rabbits and evoked bactericidal antibodies against all 30 vaccine serotypes of GAS. In addition, the vaccine antisera also contained significant levels of bactericidal antibodies against 24 of 40 non-vaccine serotypes of GAS. These results indicate that the potential efficacy of the new multivalent vaccine may be greater than predicted based on the "type-specific" M peptides represented.
我们之前的研究表明，含有多达 26 种 A 群链球菌（GAS）不同血清型氨基末端 M 蛋白片段的重组多价疫苗能够在动物和人体内诱导调理抗体。在本研究中，我们构建了一种新型的 30 价疫苗，其中包含了北美和欧洲流行的 GAS 血清型的 M 蛋白肽。该疫苗在兔子体内具有免疫原性，并能诱导针对 30 种 GAS 疫苗血清型的杀菌抗体。此外，疫苗抗血清还含有针对 40 种非疫苗 GAS 血清型中的 24 种的显著水平的杀菌抗体。这些结果表明，新型多价疫苗的潜在疗效可能大于基于所代表的“型特异性”M 肽的预测。
